A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor: Fondazione Italiana Linfomi - ETS
Terminated
The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.
Other terminated trials from Fondazione Italiana Linfomi - ETS
Other Diffuse Large B-Cell Lymphoma trials with similar outcome
This PHASE3 trial investigates Diffuse Large B-Cell Lymphoma and is currently terminated or withdrawn. Fondazione Italiana Linfomi - ETS leads this study, which shows 18 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Mar 2022 — Jun 2023 [monthly]
Terminated PHASE3
▶ Show 13 earlier versions
-
Jan 2022 — Mar 2022 [monthly]
Terminated PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
May 2019 — Nov 2020 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Aug 2018 — May 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
May 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Apr 2018 — May 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fondazione Italiana Linfomi - ETS
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Aarau, Switzerland , Aarhus, Denmark , Aberdeen, United Kingdom , Aichi, Japan , Albany, United States , Alessandria, Italy , Amarillo, United States , Aurora, United States , Bangkok, Thailand and 177 more locations